BeOne Medicines is a global oncology company that discovers and develops innovative cancer treatments across hematology and solid tumor markets, selling through regulatory approvals and third-party reimbursement systems worldwide. The company operates through a portfolio of proprietary medicines—including a leading BTK inhibitor for blood cancers and a PD-1 monoclonal antibody for solid tumors—alongside in-licensed oncology products primarily for the China market. BeOne generates revenue from product sales, maintains an integrated clinical development infrastructure of approximately 3,800 people across six continents, operates multiple manufacturing facilities, and leverages diverse technology platforms including small molecules, protein degraders, bispecific antibodies, and antibody-drug conjugates to sustain a pipeline of cancer therapies at various development stages.